| Literature DB >> 34884191 |
Chung-Kuang Ko1, Kuan-I Huang2, Fang-Ying Su3, Mei-Lan Ko4,5.
Abstract
Peripapillary and macular vessel density (VD) are reduced in myopic non-glaucomatous eyes, the dynamic range of VD may be decreased by myopia, and whether VD measurement has the potential in differentiating stages of glaucoma severity in patients with myopic glaucoma remains questionable. This observational, cross-sectional study aimed to clarify the changes in peripapillary and macular VDs in preperimetric glaucoma (PPG) and primary open-angle glaucoma in the early, moderate, and late stages. A total of 1228 eyes from 661 participants (540 normal, 67 PPG, and 521 glaucomatous) were included. Participants underwent free blood tests at the internal medicine clinic to retrieve systemic data. Patients with glaucoma were grouped by disease severity, defined by glaucomatous visual field mean defect, including early-(224 eyes), moderate-(103 eyes), and late-stage glaucoma (194 eyes), and further divided into advanced (158 eyes) and terminal glaucoma (36 eyes). Macular VD, peripapillary VD, circumpapillary retinal nerve fiber layer (cpRNFL) thickness, and ganglion cell complex (GCC) thickness were evaluated and divided into superior and inferior parts. One-way analysis of variance was performed, followed by Tukey's post-hoc test. The peripapillary VD was significantly different between the healthy and PPG groups and the early-, moderate-, and late-stage glaucoma subgroups (all p < 0.001). Peripapillary VD measurements are helpful in differentiating the various stages of glaucoma even in patients with myopic glaucoma.Entities:
Keywords: glaucoma; macula; myopia; optical coherence tomography-angiography; peripapillary; vessel density
Year: 2021 PMID: 34884191 PMCID: PMC8658219 DOI: 10.3390/jcm10235490
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Figure 1Flow chart of eligible eyes selection. After manual evaluation of the raw data to exclude ineligible eyes, we grouped the eyes into control eyes (540 eyes), PPG eyes (67 eyes), and glaucoma eyes (521 eyes) for the analysis. BCVA, best corrected visual acuity; PPG, pre-perimetric glaucoma.
Demographics and Characteristics of the Control and Glaucoma groups.
| Control | Glaucoma | ||
|---|---|---|---|
| Age (years) | 45.19 ± 14.23 | 51.95 ± 14.12 | <0.001 |
| <40 | 109 (37.6%) | 76 (20.5%) | |
| 40–60 | 142 (49.0%) | 190 (51.2%) | |
| ≥60 | 39(13.5%) | 105 (28.3%) | |
| Gender | <0.001 | ||
| Male | 91 (31.4%) | 231 (62.3%) | |
| Female | 199 (68.6%) | 140 (37.7%) | |
| SBP (mmHg) | 123.81 ± 17.91 | 128.77 ± 18.61 | <0.001 |
| DBP (mmHg) | 73.26 ± 12.35 | 76.07 ± 12.1 | 0.004 |
| MAP (mmHg) | 90.11 ± 13.31 | 93.63 ± 13.07 | <0.001 |
| HR (/min) | 79.34 ± 12.46 | 75.31 ± 12.03 | <0.0001 |
| TG (mg/dL) | 106.84 ± 70.33 | 117.08 ± 55.63 | 0.192 |
| HDL (mg/dL) | 56.04 ± 13.75 | 51.86 ± 15.29 | 0.024 |
| LDL (mg/dL) | 113.89 ± 33.05 | 108.98 ± 30.45 | 0.292 |
| AC sugar (mg/dL) | 94.86 ± 14.73 | 104.39 ± 23.19 | <0.001 |
| HbA1c (%) | 5.98 ± 0.65 | 6.01 ± 0.88 | 0.798 |
| ALT (U/L) | 21.54 ± 18.05 | 27.21 ± 19.37 | 0.007 |
| Creatinine (mg/dL) | 0.9 ± 1.22 | 0.95 ± 0.77 | 0.641 |
| eGFR (mL/min/1.73 m2) | 99.83 ± 22.24 | 91.92 ± 21.34 | 0.001 |
| Uric Acid(mg/dL) | 5.24 ± 1.51 | 5.94 ± 1.36 | <0.001 |
Note. SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure; HR, heart rate; TG, triglyceride; HDL, high-density lipoprotein (cholesterol); LDL, low-density lipoprotein (cholesterol); ALT, aspartate aminotransferase; eGFR, estimated glomerular filtration rate.
Demographics and Characteristics of the Control and Glaucoma groups after Gender and Age Matching.
| Control | Glaucoma | ||
|---|---|---|---|
| Age (years) | 47.4 ± 15.2 | 49.3 ± 14.7 | 0.08 |
| <40 | 62 (31.0%) | 51 (25.5%) | |
| 40–60 | 101 (50.5%) | 107 (53.5%) | |
| ≥60 | 37 (18.5%) | 42 (21.0%) | |
| Gender | 0.19 | ||
| Male | 88 (44.0%) | 75 (37.5%) | |
| Female | 112 (56.0%) | 125 (62.5%) | |
| SBP (mmHg) | 124.7 ± 17.9 | 126.9 ± 19.4 | 0.23 |
| DBP (mmHg) | 74.2 ± 11.8 | 73.3 ± 11.5 | 0.45 |
| MAP (mmHg) | 91.0 ± 12.9 | 91.2 ± 13.1 | 0.91 |
| HR (/min) | 78.4 ± 13.1 | 76.3 ± 12.4 | 0.10 |
| TG (mg/dL) | 114.7 ± 84.5 | 102.9 ± 52.2 | 0.29 |
| HDL (mg/dL) | 56.1 ± 15.0 | 54.7 ± 15.2 | 0.56 |
| LDL (mg/dL) | 107.2 ± 31.0 | 104.9 ± 31.2 | 0.70 |
| AC sugar (mg/dL) | 96.5 ± 16.1 | 101.9 ± 24.2 | 0.10 |
| HbA1c (%) | 6.0 ± 0.7 | 5.8 ± 0.7 | 0.25 |
| ALT (U/L) | 23.6 ± 20.9 | 25.8 ± 21.1 | 0.47 |
| Creatinine (mg/dL) | 1.0 ± 1.3 | 0.9 ± 0.4 | 0.45 |
| eGFR (mL/min/1.73 m2) | 97.1 ± 21.4 | 95.6 ± 22.4 | 0.63 |
| Uric Acid(mg/dL) | 5.5 ± 1.8 | 5.6 ± 1.5 | 0.93 |
Note. SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure; HR, heart rate; TG, triglyceride; HDL, high-density lipoprotein (cholesterol); LDL, low-density lipoprotein (cholesterol); ALT, aspartate aminotransferase; eGFR, estimated glomerular filtration rate.
Ocular Data of the Control and Glaucoma groups after Gender and Age Matching.
| Control Eyes ( | Glaucoma Eyes ( | ||
|---|---|---|---|
| OD/OS | 0.76 | ||
| OD | 173 (50.4%) | 177 (51.6%) | |
| OS | 170 (49.6%) | 166 (48.4%) | |
| VA (logMAR) | 0.1 ± 0.2 | 0.3 ± 0.6 | <0.001 |
| AL (mm) | 25.1 ± 1.7 | 25.7 ± 2.1 | <0.001 |
| <24 | 100 (29.2%) | 75 (22.0%) | <0.001 |
| 24–25.9 | 145 (42.3%) | 101 (29.6%) | |
| ≥26 | 98 (28.6%) | 165 (48.4%) | |
| IOP (mmHg) | 14.9 ± 3.6 | 14.7 ± 4.1 | 0.509 |
| CCT (µm) | 547.1 ± 33.2 | 535.4 ± 37.9 | <0.001 |
| VF: Mean Defect | −1.2 ± 1.8 | −8.2 ± 8.3 | <0.001 |
| Macular VD (%) | |||
| Superior | 50.1 ± 4.7 | 43.8 ± 7.4 | <0.001 |
| Center | 18.7 ± 6.4 | 16.4 ± 7.0 | <0.001 |
| Inferior | 49.6 ± 4.7 | 41.4 ± 8.1 | <0.001 |
| Peripapillary VD (%) | |||
| Superior | 51.6 ± 5.0 | 40.5 ± 10.7 | <0.001 |
| Inferior | 52.7 ± 5.0 | 37.9 ± 10.5 | <0.001 |
| cpRNFL Thickness (µm) | |||
| Superior | 100.0 ± 9.6 | 78.2 ± 15.5 | <0.001 |
| Inferior | 96.1 ± 9.1 | 72.0 ± 15.1 | <0.001 |
| GCC Thickness (µm) | |||
| Superior | 95.6 ± 5.5 | 78.4 ± 12.5 | <0.001 |
| Inferior | 95.0 ± 5.5 | 72.3 ± 13.2 | <0.001 |
| Cup/Disc Ratio (%) | 51.2 ± 18.6 | 79.2 ± 16.0 | <0.001 |
| Rim Area (0.01 mm2) | 131.1 ± 36.9 | 75.9 ± 39.8 | <0.001 |
| Disc Area (0.01 mm2) | 203.5 ± 49.4 | 212.1 ± 61.5 | 0.046 |
Note. OD, right eye; OS, left eye; VA, visual acuity; AL, axial length; CCT, central corneal thickness; VF, visual field; VD, vessel density; cpRNFL, circumpapillary retinal nerve fiber layer; GCC, ganglion cell complex.
Demographics and Clinical Characteristics after Gender and Age Matching for Groups of Glaucomatous Subjects and Control Subjects.
| A vs. B | A vs. C | B vs. C | |||||||
|---|---|---|---|---|---|---|---|---|---|
| a | b | c | |||||||
| Age | 44.7 ± 13.9 | 48.6 ± 15.7 | 47.7 ± 14.4 | 48.2 ± 12.9 | 46.9 ± 12.2 | 50.6 ± 14.1 | 0.12 | 0.52 | 0.33 |
| <40 | 112 (38.9%) | 9 (28.1%) | 81 (25.8%) | 95 (30.2%) | 15 (24.2%) | 75 (24.2%) | 0.24 | 0.95 | 0.20 |
| 40–60 | 142 (49.3%) | 18 (56.3%) | 177 (56.4%) | 150 (47.8%) | 40 (64.5%) | 163 (52.6%) | |||
| ≥60 | 34 (11.8%) | 5 (15.6%) | 56 (17.8%) | 69 (22.0%) | 7 (11.3%) | 72 (23.2%) | |||
| Gender | 1.00 | 1.00 | 0.23 | ||||||
| Male | 72 (25.0%) | 8 (25.0%) | 156 (49.7%) | 156 (49.7%) | 43 (69.3%) | 190 (61.3%) | |||
| Female | 216 (75.0%) | 24 (75.0%) | 158 (50.3%) | 158 (50.3%) | 19 (30.7%) | 120 (38.7%) | |||
| SBP | 122.5 ± 17.7 | 130.3 ± 18.4 | 126.2 ± 18.4 | 125.9 ± 17.5 | 129.5 ± 16.0 | 129.0 ± 18.6 | 0.03 | 0.85 | 0.82 |
| DBP | 72.0 ± 12.0 | 76.8 ± 13.0 | 75.4 ± 12.0 | 74.5 ± 11.7 | 78.6 ± 12.5 | 76.0 ± 12.3 | 0.03 | 0.35 | 0.13 |
| MAP | 88.9 ± 13.0 | 94.7 ± 13.5 | 92.4 ± 13.2 | 91.7 ± 12.5 | 95.6 ± 12.7 | 93.6 ± 13.1 | 0.02 | 0.51 | 0.28 |
| HR | 79.4 ± 12.4 | 75.5 ± 9.8 | 78.8 ± 12.3 | 74.7 ± 11.5 | 74.9 ± 10.1 | 75.5 ± 12.3 | 0.08 | <0.001 | 0.71 |
| TG | 105.7 ± 69.9 | 102.3 ± 45.6 | 122.7 ± 87.1 | 113.1 ± 49.7 | 108.6 ± 45.0 | 116.9 ± 57.2 | 0.64 | 0.27 | 0.52 |
| HDL | 55.9 ± 13.5 | 55.2 ± 12.4 | 52.4 ± 14.1 | 52.5 ± 14.8 | 52.0 ± 11.7 | 50.4 ± 15.5 | 0.77 | 0.96 | 0.63 |
| LDL | 113.7 ± 32.8 | 115.2 ± 35.1 | 113.6 ± 34.1 | 109.1 ± 29.1 | 119.2 ± 27.4 | 113.4 ± 31.7 | 0.89 | 0.35 | 0.47 |
| AC sugar | 94.1 ± 14.3 | 93.4 ± 8.1 | 96.9 ± 14.1 | 100.3 ± 19.8 | 95.4 ± 8.1 | 104.2 ± 22.5 | 0.70 | 0.12 | 0.001 |
| HbA1c | 6.0 ± 0.7 | 5.1 ± 0.3 | 6.0 ± 0.5 | 6.1 ± 1.1 | 5.4 ± 0.6 | 6.1 ± 0.9 | 0.02 | 0.33 | 0.01 |
| ALT | 20.2 ± 17.1 | 32.0 ± 21.9 | 22.2 ± 11.9 | 23.8 ± 16.2 | 31.1 ± 21.7 | 25.7 ± 18.3 | 0.03 | 0.38 | 0.18 |
| Creatinine | 0.9 ± 1.2 | 0.8 ± 0.2 | 1.0 ± 1.5 | 0.9 ± 0.8 | 0.9 ± 0.2 | 0.9 ± 0.8 | 0.49 | 0.47 | 0.27 |
| eGFR | 100.9 ± 21.3 | 99.2 ± 16.6 | 95.0 ± 21.4 | 95.9 ± 21.2 | 97.9 ± 17.7 | 93.0 ± 21.2 | 0.37 | 0.71 | 0.26 |
| Uric Acid | 5.1 ± 1.3 | 5.3 ± 1.3 | 5.7 ± 1.6 | 5.9 ± 1.3 | 5.9 ± 1.3 | 6.0 ± 1.4 | 0.51 | 0.46 | 0.85 |
Group A, control eyes; Group B, pre-perimetric glaucoma eyes; Group C, glaucoma eyes; a p-value, A vs. B; b p-value, A vs. C; c p-value, B vs. C; Unit. Age (years); SBP (mmHg); DBP (mmHg); MAP (mmHg); HR (/min); TG (mg/dL); HDL (mg/dL); LDL (mg/dL); AC sugar (mg/dL); HbA1c (%); ALT (U/L); Creatinine (mg/dL); eGFR (mL/min/1.73 m2); Uric Acid (mg/dL); Abbreviations. SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure; HR, heart rate; TG, triglyceride; HDL, high-density lipoprotein (cholesterol); LDL, low-density lipoprotein (cholesterol); ALT, aspartate aminotransferase; eGFR, estimated glomerular filtration rate.
Ocular Data after Gender and Age Matching for Groups of Glaucomatous subjects and Control subjects.
| A vs. B | A vs. C | B vs. C | |||||||
|---|---|---|---|---|---|---|---|---|---|
| a | b | c | |||||||
| OD/OS | 0.68 | 0.58 | 0.68 | ||||||
| OD | 151 (52.4%) | 18 (56.3%) | 160 (51.0%) | 153 (48.7%) | 30 (48.4%) | 159 (51.3%) | |||
| OS | 137 (47.6%) | 14 (43.7%) | 154 (49.0%) | 161 (51.3%) | 32 (51.6%) | 151 (48.7%) | |||
| VA (logMAR) | 0.1 ± 0.2 | 0.2 ± 0.6 | 0.1 ± 0.2 | 0.3 ± 0.5 | 0.3 ± 0.6 | 0.4 ± 0.7 | 0.37 | <0.001 | 0.20 |
| AL (mm) | 25.2 ± 1.8 | 25.6 ± 1.8 | 25.1 ± 1.8 | 25.7 ± 2.1 | 25.9 ± 1.9 | 25.6 ± 2.4 | 0.22 | <0.001 | 0.37 |
| <24 | 78 (27.1%) | 7 (21.9%) | 97 (30.9%) | 71 (22.8%) | 13 (21.0%) | 86 (27.8%) | |||
| 24–25.9 | 121 (42.0%) | 8 (25.0%) | 118 (37.6%) | 100 (32.0%) | 16 (25.8%) | 87 (28.2%) | |||
| 26 | 89 (30.9%) | 17 (53.1%) | 99 (31.5%) | 141 (45.2%) | 33 (53.2%) | 136 (44.0%) | |||
| IOP (mmHg) | 14.6 ± 3.4 | 14.9 ± 3.3 | 14.8 ± 3.6 | 14.8 ± 4.0 | 15.1 ± 4.0 | 14.7 ± 3.8 | 0.66 | 0.84 | 0.45 |
| CCT (µm) | 543.9 ± 35.9 | 542.2 ± 31.0 | 544.0 ± 35.4 | 536.4 ± 34.1 | 530.7 ± 44.7 | 536.5 ± 36.0 | 0.80 | 0.007 | 0.34 |
| VF | −1.4 ± 1.8 | −1.4 ± 1.5 | −1.2 ± 1.9 | −9.0 ± 8.6 | −1.0 ± 1.3 | −10.3 ± 9.0 | 0.98 | <0.001 | <0.001 |
| Macular VD (%) | |||||||||
| Superior | 50.1 ± 4.8 | 47.3 ± 5.1 | 49.9 ± 5.3 | 43.5 ± 7.1 | 46.4 ± 6.7 | 42.9 ± 7.5 | 0.002 | <0.001 | <0.001 |
| Center | 18.4 ± 6.8 | 18.0 ± 6.4 | 18.6 ± 6.3 | 16.1 ± 7.0 | 17.8 ± 6.2 | 16.0 ± 6.9 | 0.72 | <0.001 | 0.06 |
| Inferior | 49.5 ± 5.1 | 46.1 ± 4.8 | 49.4 ± 5.4 | 41.0 ± 7.7 | 45.7 ± 6.1 | 40.2 ± 8.0 | 0.001 | <0.001 | <0.001 |
| Peripapillary VD (%) | |||||||||
| Superior | 51.7 ± 5.2 | 47.1 ± 6.4 | 51.3 ± 5.3 | 39.1 ± 10.6 | 47.3 ± 5.9 | 37.9 ± 10.6 | <0.001 | <0.001 | <0.001 |
| Inferior | 52.7 ± 5.4 | 48.5 ± 5.2 | 52.4 ± 5.4 | 36.6 ± 10.2 | 47.4 ± 5.1 | 35.4 ± 10.3 | <0.001 | <0.001 | <0.001 |
| cpRNFL Thickness (µm) | |||||||||
| Superior | 101.0 ± 10.1 | 85.6 ± 10.2 | 100.8 ± 10.0 | 76.0 ± 16.0 | 86.6 ± 10.3 | 75.1 ± 15.4 | <0.001 | <0.001 | <0.001 |
| Inferior | 96.9 ± 9.4 | 85.1 ± 9.8 | 96.3 ± 8.9 | 69.3 ± 15.0 | 81.5 ± 10.7 | 67.8 ± 13.4 | <0.001 | <0.001 | <0.001 |
| GCC Thickness (µm) | |||||||||
| Superior | 96.0 ± 5.9 | 86.3 ± 7.4 | 95.8 ± 5.4 | 76.6 ± 12.2 | 85.9 ± 8.0 | 76.3 ± 13.0 | <0.001 | <0.001 | <0.001 |
| Inferior | 95.4 ± 5.9 | 83.5 ± 7.3 | 95.1 ± 5.6 | 70.5 ± 12.5 | 81.3 ± 8.1 | 70.0 ± 12.8 | <0.001 | <0.001 | <0.001 |
| C/D Ratio | 49.8 ± 19.5 | 66.5 ± 18.6 | 51.5 ± 19.4 | 80.7 ± 15.6 | 70.5 ± 14.8 | 82.5 ± 13.4 | <0.001 | <0.001 | <0.001 |
| Rim Area | 133.3 ± 37.2 | 109.3 ± 63.7 | 130.8 ± 37.1 | 72.0 ± 39.1 | 98.1 ± 50.8 | 69.8 ± 37.9 | 0.04 | <0.001 | <0.001 |
| Disc Area | 203.5 ± 48.4 | 218.9 ± 56.2 | 204.2 ± 49.4 | 212.6 ± 60.1 | 212.8 ± 48.8 | 216.4 ± 59.5 | 0.09 | 0.06 | 0.66 |
Group A, control eyes; Group B, pre-perimetric glaucoma eyes; Group C, glaucoma eyes; a p-value, A vs. B; b p-value, A vs. C; c p-value, B vs. C; Unit. VA (logMAR); VF (mean deviation); VD (%); thickness (µm); C/D ratio (%); Rim area (0.01 mm2); Disc area (0.01 mm2); Abbreviation. OD, right eye; OS, left eye; VA, visual acuity; AL, axial length; CCT, central corneal thickness; VF, visual field; VD, vessel density; cpRNFL, circumpapillary retinal nerve fiber layer; GCC, ganglion cell complex; C/D Ratio, cup to disc ratio.
One Way Analysis of OCTA parameters and OCT measurement among the glaucoma severity groups.
| Group 0 | Group 1 | Group 2 | Group 3 | Group 4 | Tukey Test | ||
|---|---|---|---|---|---|---|---|
| Age (years) | 44.4 ± 13.8 | 45.7 ± 12.7 | 48.3 ± 12.2 | 51.3 ± 12.8 | 56.1 ± 14.5 | <0.001 | 4 > 0, 1, 2, 3 |
| Axial Length (mm) | 25.2 ± 1.7 | 25.9 ± 1.8 | 25.9 ± 1.8 | 26.3 ± 2.8 | 25.1 ± 2.2 | <0.001 | 1, 2, 3 > 0, 4 |
| Gender | 0.463 | ||||||
| Male | 169 (31.3%) | 43 (64.2%) | 137 (61.2%) | 69 (67.7%) | 132 (68.0%) | ||
| Female | 371 (68.7%) | 24 (35.8%) | 87 (38.8%) | 33 (32.4%) | 62 (32.0%) | ||
| Macular VD (%) | |||||||
| Superior | 50.3 ± 4.8 | 46.6 ± 6.5 | 46.1 ± 6.0 | 41.2 ± 6.6 | 38.1 ± 7.5 | <0.001 | 0 > 1, 2 > 3 > 4 |
| Center | 18.4 ± 6.4 | 18.1 ± 6.1 | 17.0 ± 6.6 | 14.7 ± 6.1 | 14.5 ± 7.0 | <0.001 | 0 > 2; 0, 1 ,2 > 3, 4 |
| Inferior | 49.7 ± 5.0 | 46.0 ± 5.9 | 43.7 ± 6.8 | 38.0 ± 7.2 | 35.2 ± 7.7 | <0.001 | 0 > 1, 2 > 3 > 4 |
| Peripapillary VD (%) | |||||||
| Superior | 51.8 ± 4.9 | 47.4 ± 5.8 | 43.6 ± 8.4 | 37.1 ± 10.2 | 29.5 ± 9.2 | <0.001 | 0 > 1 > 2 > 3 > 4 |
| Inferior | 52.9 ± 5.2 | 47.6 ± 5.0 | 41.5 ± 8.1 | 33.2 ± 9.2 | 26.9 ± 7.8 | <0.001 | 0 > 1 > 2 > 3 > 4 |
| cpRNFL Thickness (µm) | |||||||
| Superior | 100.8 ± 9.7 | 86.8 ± 10.4 | 81.2 ± 13.5 | 74.0 ± 14.6 | 67.1 ± 14.9 | <0.001 | 0 > 1 > 2 > 3 > 4 |
| Inferior | 96.8 ± 9.0 | 82.0 ± 10.7 | 74.6 ± 12.8 | 65.2 ± 14.0 | 61.1 ± 13.4 | <0.001 | 0 > 1 > 2 > 3 > 4 |
| GCC Thickness (µm) | |||||||
| Superior | 95.9 ± 5.8 | 86.0 ± 7.8 | 81.1 ± 10.2 | 73.9 ± 12.6 | 69.4 ± 12.4 | <0.001 | 0 > 1 > 2 > 3 > 4 |
| Inferior | 95.3 ± 5.7 | 81.5 ± 8.0 | 75.0 ± 12.1 | 65.9 ± 10.4 | 64.2 ± 11.1 | <0.001 | 0 > 1 > 2 > 3 > 4 |
| Cup/Disc Ratio (%) | 49.7 ± 19.5 | 69.5 ± 16.0 | 77.5 ± 14.0 | 83.4 ± 13.7 | 89.5 ± 11.0 | <0.001 | 0 < 1 < 2 < 3 < 4 |
| Rim Area (0.01 mm2) | 133.3 ± 36.7 | 100.1 ± 50.2 | 78.5 ± 33.9 | 69.8 ± 38.2 | 51.6 ± 30.3 | <0.001 | 0 > 1 > 2, 3 > 4 |
| Disc Area (0.01 mm2) | 203.4 ± 48.6 | 213.9 ± 49.8 | 209.5 ± 51.8 | 221.0 ± 81.9 | 216.7 ± 60.6 | 0.006 |
Group 0, control eyes; Group 1, pre-perimetric glaucoma eyes; Group 2, early glaucoma eyes with −2 dB > VF(MD) ≥ −6 dB; Group 3, moderate glaucoma eyes with −6 dB > VF(MD) ≥ −12 dB; Group 4, late glaucoma eyes with VF(MD) < −12 dB; OD, right eye; OS, left eye; VA, visual acuity; AL, axial length; CCT, central corneal thickness; VF, visual field; VD, vessel density; cpRNFL, circumpapillary retinal nerve fiber layer; GCC, ganglion cell complex; MD, mean deviation.The OCTA-based VD and OCT-based structural thickness of the two groups (advanced, terminal stage) are shown in Table 7. No significant difference was noted between the two groups in terms of peripapillary and macular VDs, cpRNFL and GCC thickness, or CD ratio.
Comparison of advanced or terminal glaucoma with OCTA parameters and OCT measurement.
| Advanced Glaucoma | Terminal Glaucoma | ||
|---|---|---|---|
| Age (years) | 56.06 ± 14.44 | 56.47 ± 14.91 | 0.879 |
| Male subjects | 110(69.62) | 22(61.11) | 0.323 |
| Macular VD (%) | |||
| Superior | 38.13 ± 7.44 | 37.84 ± 7.93 | 0.845 |
| Center | 13.98 ± 6.48 | 17.19 ± 8.88 | 0.064 |
| Inferior | 35.15 ± 7.56 | 35.64 ± 8.36 | 0.759 |
| Peripapillary VD (%) | |||
| Superior | 29.68 ± 8.84 | 28.70 ± 11.02 | 0.635 |
| Inferior | 26.86 ± 7.33 | 27.16 ± 9.92 | 0.876 |
| cpRNFL Thickness (µm) | |||
| Superior | 66.99 ± 13.61 | 67.75 ± 19.56 | 0.827 |
| Inferior | 60.94 ± 13.20 | 61.72 ± 14.21 | 0.753 |
| GCC Thickness (µm) | |||
| Superior | 69.58 ± 11.95 | 68.56 ± 14.44 | 0.667 |
| Inferior | 63.96 ± 10.89 | 65.26 ± 11.81 | 0.536 |
| Cup/Disc Ratio (%) | 90.04 ± 9.79 | 87.11 ± 15.17 | 0.274 |
| Rim Area (0.01 mm2) | 49.92 ± 25.06 | 59.03 ± 46.49 | 0.262 |
| Disc Area (0.01 mm2) | 217.80 ± 59.97 | 211.69 ± 63.65 | 0.587 |
| AL (mm) | 25.07 ± 2.19 | 24.98 ± 2.24 | 0.818 |
| VF (mean defect) | −20.24 ± 5.49 | −31.71 ± 0.87 | <0.001 |
| VA (logMAR) | 0.55 ± 0.79 | 0.91 ± 1.20 | 0.148 |
Note. Advanced glaucoma, −12 dB > VF(MD) ≥ −30 dB; Terminal glaucoma, VF(MD) < −30 dB; Abbreviation. VD, vessel density; cpRNFL, circumpapillary retinal nerve fiber layer; GCC, ganglion cell complex; VA, visual acuity; AL, axial length.
Multivariable linear regression models with generalized estimating equation (GEE) model * for correlations between visual field in mean defect with OCTA parameters and OCT measurement.
| β | SE | ||
|---|---|---|---|
| Macular VD (%) | |||
| Superior | 0.55 | 0.05 | <0.001 |
| Center | 0.16 | 0.10 | 0.123 |
| Inferior | 0.54 | 0.05 | <0.001 |
| Peripapillary VD (%) | |||
| Superior | 0.47 | 0.04 | <0.001 |
| Inferior | 0.53 | 0.03 | <0.001 |
| cpRNFL Thickness (µm) | |||
| Superior | 0.24 | 0.03 | <0.001 |
| Inferior | 0.25 | 0.03 | <0.001 |
| GCC Thickness (µm) | |||
| Superior | 0.38 | 0.03 | <0.001 |
| Inferior | 0.35 | 0.03 | <0.001 |
| Cup/Disc Ratio (%) | −0.23 | 0.04 | <0.001 |
| Rim Area (0.01 mm2) | 0.07 | 0.01 | <0.001 |
| Disc Area (0.01 mm2) | 0.00 | 0.01 | 0.936 |
OCTA, optical coherence tomography angiography; VD, vessel density; cpRNFL, circumpapillary retinal nerve fiber layer; GCC, ganglion cell complex. * Adjusted for age, gender, axial length.
Comparison of percentage loss hemifield asymmetry of corresponding regions of OCTA parameters between pre-perimetric glaucoma eyes and glaucoma eyes.
| PPG † | Glaucoma ‡ | |||
|---|---|---|---|---|
| Macular VD | ||||
| Superior | 0.07 ± 0.13 | 0.94 | 0.16 ± 0.15 | <0.001 |
| Inferior | 0.08 ± 0.12 | 0.20 ± 0.16 | ||
| Peripapillary VD | ||||
| Superior | 0.09 ± 0.11 | 0.34 | 0.28 ± 0.21 | <0.001 |
| Inferior | 0.10 ± 0.10 | 0.35 ± 0.20 | ||
| cpRNFL Thickness | ||||
| Superior | 0.14 ± 0.10 | 0.36 | 0.26 ± 0.15 | <0.001 |
| Inferior | 0.15 ± 0.11 | 0.30 ± 0.15 | ||
| GCC Thickness | ||||
| Superior | 0.10 ± 0.08 | <0.001 | 0.21 ± 0.13 | <0.001 |
| Inferior | 0.14 ± 0.08 | 0.27 ± 0.13 |
PPG, pre-perimetric glaucoma; VD, vessel density; cpRNFL, circumpapillary retinal nerve fiber layer; GCC, ganglion cell complex; * Two sample pair t-test; † PPG group = (Mean Control –PPG)/Mean Control; ‡ G group = (Mean Control – G)/Mean Control.
Pearson correlation coefficient between OCTA parameters with OCT measurement in same region.
|
|
| ||
| Superior | GCC Thickness | 0.658 | <0.001 |
| Inferior | GCC Thickness | 0.636 | <0.001 |
| Superior | cpRNFL Thickness | 0.674 | <0.001 |
| Inferior | cpRNFL Thickness | 0.666 | <0.001 |
OCTA, optical coherence tomography angiography; VD, vessel density; cpRNFL, circumpapillary retinal nerve fiber layer; GCC, ganglion cell complex.
Multivariable linear regression models with generalized estimating equation (GEE) model * for correlations between OCTA parameters with OCT measurement in same region: change in structural thickness related with VD.
| β | SE | |||
|---|---|---|---|---|
| Superior | GCC Thickness | 1.04 | 0.05 | <0.001 |
| Inferior | GCC Thickness | 0.94 | 0.05 | <0.001 |
| Superior | cpRNFL Thickness | 0.90 | 0.06 | <0.001 |
| Inferior | cpRNFL Thickness | 0.91 | 0.05 | <0.001 |
OCTA, optical coherence tomography angiography; VD, vessel density; cpRNFL, circumpapillary retinal nerve fiber layer; GCC, ganglion cell complex; * Adjusted for age, sex, axial length.
Proportion of higher myopia with more VF defect in all patients with glaucoma.
| Glaucoma Subjects, |
| % |
|---|---|---|
| Higher myopia with more VF defect a | 161 | 50.6 |
| Others b | 157 | 49.4 |
VF, visual field; a In bilateral eyes: AL differences (mm) > 0 and VF differences (dB) < 0 or AL differences (mm) < 0 and VF differences (dB) > 0; b In bilateral eyes: AL differences (mm) ≤ 0 and VF differences (dB) ≤ 0 or AL differences (mm) ≥ 0 and VF differences (dB) ≥ 0.